STOCK TITAN

Rocket Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announces key upcoming presentations: President Kinnari Patel will present at the Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference on April 1 at 8:00 a.m. ET, and CEO Gaurav Shah will speak at the 21st Annual Needham Virtual Healthcare Conference on April 11 at 10:15 a.m. ET. The live webcasts will be accessible on the company's website, with replays available post-event. Rocket focuses on genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease.

Positive
  • None.
Negative
  • None.

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Kinnari Patel, Pharm.D., MBA, President and Chief Operating Officer, will deliver a virtual company presentation at the Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference on Friday, April 1 at 8:00 a.m. ET. Gaurav Shah, M.D., Chief Executive Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11 at 10:15 a.m. ET.

A live audio webcast of the presentations will be available under “Events” in the Investors section of the Company’s website at https://ir.rocketpharma.com. The webcast replay will be available on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding its guidance for 2022 in light of COVID-19, the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, Rocket’s plans for the advancement of its Danon Disease program following the lifting of the FDA’s clinical hold and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed November 5, 2021 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Media

Kevin Giordano

Director, Corporate Communications

kgiordano@rocketpharma.com

Investors

Jessie Yeung, M.B.A.

Vice President, Investor Relations and Corporate Finance

investors@rocketpharma.com

Source: Rocket Pharmaceuticals, Inc.

FAQ

What is Rocket Pharmaceuticals' presentation schedule for April 2023?

Rocket Pharmaceuticals will present at the Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference on April 1 at 8:00 a.m. ET and at the 21st Annual Needham Virtual Healthcare Conference on April 11 at 10:15 a.m. ET.

Where can I watch Rocket Pharmaceuticals' presentations?

The live audio webcasts of Rocket Pharmaceuticals' presentations can be found under the 'Events' section of the Company's website.

What disorders does Rocket Pharmaceuticals focus on in its therapies?

Rocket Pharmaceuticals develops therapies for rare childhood disorders, including Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Danon Disease.

What types of genetic therapies does Rocket Pharmaceuticals offer?

Rocket Pharmaceuticals offers lentiviral vector (LVV)-based and adeno-associated virus (AAV)-based gene therapies targeting complex and rare genetic disorders.

What is the stock symbol for Rocket Pharmaceuticals?

The stock symbol for Rocket Pharmaceuticals is RCKT, listed on NASDAQ.

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

RCKT Rankings

RCKT Latest News

RCKT Stock Data

1.22B
98.79M
3.38%
107.09%
12.17%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK